KWF
Biomarkers 2026 — Clinical Validation of Biomarkers
Full proposal deadline was 14 April 2026 (12:00 noon); funding decision July 2026 — call appears closed
Last verified:
The Biomarkers 2026 call funds €0.8-€2 million per consortium over 2-5 years for clinical validation of cancer biomarkers at TRL5-6, moving known markers toward near-term clinical practice. Applicants must form multidisciplinary consortia of at least four parties (including academic, hospital, patient groups, and optional industry) based in the Netherlands. This is a closed call (deadline 14 April 2026, funding decision July 2026); KWF runs similar biomarker validation calls periodically.
Details
| Funder | KWF |
| Budget | €0.8M–€2M per proposal (total call budget €4M–€6M) |
| Duration | 2–5 years |
| Consortium | Required — minimum 4 participating parties (multidisciplinary consortium; private partners allowed) |
| Application | 2-stage: pre-proposal (closed 2 Dec 2025) → full proposal (closed 14 Apr 2026) → interviews (Jun 2026) |
| TRL | 5-6 |
| Eligible countries | NL |
Eligibility & scope
Multidisciplinary consortium (≥4 parties) to clinically validate known cancer biomarkers at TRL5/6 for near-term clinical practice. Mandatory components: (early) HTA, patient involvement (PACO review 30% weight), FAIR data-sharing plan, project manager. For-profit partners >250 FTE must co-finance 10% of KWF budget. All cancer types in scope; biomarkers for treatment side-effects are out of scope.
Who Should Apply
- •Consortia of ≥4 parties: academic researchers, hospital clinicians, patient representatives, and optional industry partners
- •Researchers and clinicians based in the Netherlands
- •Teams with a known cancer biomarker at TRL5-6 ready for clinical translation
- •Projects that include HTA, patient co-design (PACO), a data-sharing plan, and a dedicated project manager
- •For-profit partners with >250 FTE must be prepared to co-finance 10% of the KWF budget
Key Dates
- •Pre-proposal deadline: 2 December 2025 (closed)
- •Full proposal deadline: 14 April 2026 (closed)
- •Interviews: June 2026; funding decision: July 2026
- •Project duration: 2-5 years
Tips for Applicants
- ✓PACO (patient review) carries 30% weight, embed patient co-investigators and lived-experience input throughout the proposal narrative, not as an afterthought.
- ✓The mandatory HTA (health technology assessment) must be credible from proposal stage; partner with someone experienced in Dutch HTA frameworks or ISPOR methods.
- ✓Data-sharing plans must be FAIR-compliant and explicit about which data, when, and to whom; vague commitments fail review. Name the repository and governance structure.
Frequently Asked Questions
How much does the Biomarkers 2026 call fund?
€0.8-€2 million per consortium, with a total call budget of €4-€6 million.
What type of consortium do I need for Biomarkers 2026?
A multidisciplinary consortium of at least 4 parties, including academic, clinical, patient, and optionally industry partners; for-profit partners with >250 FTE must co-finance 10% of the KWF budget.
Which biomarkers are eligible for Biomarkers 2026?
Known cancer biomarkers at TRL5-6 for any cancer type, focused on near-term clinical practice validation; biomarkers for treatment side-effects are not eligible.
Is Biomarkers 2026 a rolling or annual call?
KWF runs periodic biomarker validation calls; Biomarkers 2026 is now closed. Check the KWF website for the next round.
What is PACO and why is it important for this grant?
PACO is patient and caregiver co-review, which carries 30% weight in evaluation. Patient representatives must be meaningfully embedded in the consortium and research design.
Related on Grantsby
- KWF writing tips & FAQ
Evaluation criteria, proposal structure, common mistakes.
Summary generated by AI based on published grant information. Always verify details on the funder's website.
More from KWF
BOOST (Bridging Obstacles for Optimal model use via Shared Technical expertise)
Deadline: 1 Jul 2026~€150,000 per projectBoost-2026
Deadline: 7 Jul 2026Pipeline
Deadline: 7 Jul 2026€1–5MKwf Pipeline 2027
Deadline: 7 Jul 2026€1-5M per proposal (indicative)KWF Pipeline Call 2026
Deadline: 7 Jul 2026€1M-€5M
Browse Related
Could Biomarkers 2026 — Clinical Validation of Biomarkers be right for you?
See your personalised match score for this grant and others in 30 seconds. No signup needed to preview.
See my matches free →